Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Case reports of new-onset myasthenia gravis after vaccination

From: Myasthenia gravis following human papillomavirus vaccination: a case report

Author Age/Sex Vaccine Type Time to onset Initial symptoms Treatment Prognosis
(Time to recovery)
Thymoma MGFA Class
Biron [9] 48/M HBV 1 mo after 2nd shot Ocular Edrophonium,, plasma exchange, cyclophosphamide, steroid Improved.
(After 30 PE)
+ I
Bahri [10] 46/F HBV 1mo after 2nd shot Ocular, bulbar Pyridostigmine, steroid Improved
(Not mentioned)
+ IIb
Takizawa [8] 69/M BCG 6 wks Ocular Pyridostigmine Improved
(70 days)
IIa
Our case 23/F HPV 3 d after 2nd shot Ocular, bulbar Pyridostigmine, steroid, IVIG Improved
(84 days)
V
  1. Mo months, d days, HBV hepatitis B vaccine, BCG Bacillus Calmette-Guerin, HPV human papillomavirus, IVIG intravenous immunoglobulin, MGFA myasthenia gravis foundation of America clinical classification